The serum YKL-40 level is a potential biomarker for OSAHS: a systematic review and meta-analysis
- 17 Downloads
Several studies have reported that serum YKL-40 level was elevated in patients with obstructive sleep apnea hypopnea syndrome (OSAHS). However, most of these studies had relatively small sample sizes and the results were inconsistent. Therefore, a meta-analysis was conducted to determine the potential role of serum YKL-40 level in OSAHS.
A systematic literature search was performed in several databases to identify eligible studies involving the relationship between serum YKL-40 level and OSAHS. The standardized mean difference (SMD) with its 95% confidence interval (CI) was calculated to determine the effect sizes.
Five eligible articles were extracted in this meta-analysis. The pooled results demonstrated that the serum YKL-40 level was significantly higher in OSAHS patients compared with their non-OSAHS controls (SMD 1.03, 95% CI 0.46, 1.59, I2 = 87%, P = 0.0004). The subgroup analysis showed that Asian (SMD 1.81, 95% CI 1.41, 2.21, I2 = 0%, P < 0.00001) and Caucasian (SMD 0.67, 95% CI 0.39, 0.96, I2 = 0%, P < 0.00001) patients with OSAHS had higher serum YKL-40 levels than their non-OSAHS controls. YKL-40 level in serum was increased in OSAHS patients with BMI < 28 (SMD 1.81, 95% CI 1.41, 2.21, I2 = 0%, P < 0.00001), as well as in patients with BMI ≥ 28 (SMD 0.57, 95% CI 0.33, 0.81, I2 = 0%, P < 0.00001). In addition, OSAHS patients with cardiac complications had a higher serum YKL-40 level compared with those patients without cardiac complications (SMD 0.80, 95% CI 0.32, 1.28, I2 = 67%, P = 0.001).
This study indicates that OSAHS patients have higher serum YKL-40 level, which may serve as a potential biomarker for OSAHS diagnosis and monitoring.
KeywordsYKL-40 OSAHS Biomarker Meta-analysis
We really thank Karan Sachdeva, a medical student in Maulana Azad Medical College in India, for helping to polish the language.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 7.Nadeem R, Molnar J, Madbouly EM, Nida M, Aggarwal S, Sajid H, Naseem J, Loomba R (2013) Serum inflammatory markers in obstructive sleep apnea: a meta-analysis. J Clin Sleep Med 9(10):1003–1012Google Scholar
- 10.Väänänen T, Vuolteenaho K, Kautiainen H, Nieminen R, Möttönen T, Hannonen P, Korpela M, Kauppi MJ, Laiho K, Kaipiainen-Seppänen O, Luosujärvi R, Uusitalo T, Uutela T, Leirisalo-Repo M, Moilanen E, NEO-RACo Study Group (2017) Glycoprotein YKL-40: a potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. PLoS One 12(8):e0183294CrossRefGoogle Scholar
- 15.Borenstein M, Hedges L, Rothstein H (2007) Meta-analysis: fixed effect vs. random effects. Available from: Meta-analysis.com. Accessed June 17, 2017
- 16.Mutlu LC, Tülübaş F, Alp R, Kaplan G, Yildiz ZD, Gürel A (2017) Serum YKL-40 level is correlated with apnea hypopnea index in patients with obstructive sleep apnea sindrome. Eur Rev Med Pharmacol Sci 21(18):4161–4166Google Scholar
- 18.Bakırcı EM, Ünver E, Değirmenci H, Kıvanç T, Günay M, Hamur H, Büyüklü M, Ceyhun G, Topal E, Çoban TA (2015) Serum YKL-40/chitinase 3-like protein 1 level is an independent predictor of atherosclerosis development in patients with obstructive sleep apnea syndrome. Turk Kardiyol Dern Ars 43(4):333–339Google Scholar
- 19.Hang YP, Xiao YL, Zhang DP, Cai HR (2011) Changes of serum levels of YKL-40 in patients with obstructive sleep apnea hypopnea syndrome and its clinical significance. Journal of Clinical Pulmonary Medicine 16(6):857–858Google Scholar
- 20.Li K, Chen Z, Qin Y, Wei YX (2019) Plasm YKL-40 levels are associated with hypertension in patients with obstructive sleep apnea. Biomed Res Int 13:5193597Google Scholar
- 28.Harutyunyan M, Gotze JP, Winkel P, Johansen JS, Hansen JF, Jensen GB, Hilden J, Kjøller E, Kolmos HJ, Gluud C, Kastrup J (2013) Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial. Immunobiology 218(7):945–951CrossRefGoogle Scholar
- 29.Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjøller E, Kolmos HJ, Lind I, Nielsen H, Gluud C, CLARICOR Trial Group (2009) High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 30(9):1066–1072CrossRefGoogle Scholar